Pete Nicholas Quotations

Our $80 per share offer for Guidant is compelling. We are providing Guidant shareholders with certainty of completion, significant upside potential and substantially more value today than the Johnson & Johnson transaction. By any objective measure, our offer is clearly superior to Johnson & Johnson's.

This transaction provides a unique opportunity to advance our strategy to further diversify and to expand the growth markets we serve.

The shareholders of both Guidant and Boston Scientific will benefit from the significant upside potential of the combined company, which will be strongly positioned in a wide range of medical markets and be supported by a more diversified base of revenues and earnings.

Our amended offer addresses all of the outstanding issues raised by Guidant's Board. We strongly encourage the Guidant Board to act in the best interests of Guidant shareholders by declaring our $73 per share offer superior to the revised $67.92 per share transaction with Johnson & Johnson.

By any objective measure, our offer is clearly superior to Johnson & Johnson's.

We are providing the shareholders of Guidant with certainty of completion, significant upside potential and substantially more value today than the Johnson & Johnson transaction. By any objective measure, our offer is clearly superior to Johnson & Johnson's.

Guidant and Boston Scientific share an entrepreneurial spirit, highly talented employees, strong customer relationships and an ability to pioneer lifesaving therapies for patients around the world.